{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T11:48:07Z","timestamp":1768736887186,"version":"3.49.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2017,5,27]],"date-time":"2017-05-27T00:00:00Z","timestamp":1495843200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Toxicol"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1007\/s00204-017-1995-9","type":"journal-article","created":{"date-parts":[[2017,5,27]],"date-time":"2017-05-27T12:51:45Z","timestamp":1495889505000},"page":"3885-3895","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Why are most phospholipidosis inducers also hERG blockers?"],"prefix":"10.1007","volume":"91","author":[{"given":"Svetoslav","family":"Slavov","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iva","family":"Stoyanova-Slavova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuaizhang","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinghua","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruili","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Menghang","family":"Xia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Beger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,5,27]]},"reference":[{"key":"1995_CR1","unstructured":"ACD\/NMR Predictor Release 12.00, version 12.5; advanced chemistry development. Toronto, Canada, 2011"},{"key":"1995_CR2","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s13321-015-0069-3","volume":"7","author":"D Bajusz","year":"2015","unstructured":"Bajusz D, R\u00e1cz A, H\u00e9berger K (2015) Why is Tanimoto index an appropriate choice for fingerprint-based similarity calculations? J Cheminform 7:20\u201333","journal-title":"J Cheminform"},{"key":"1995_CR3","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.tiv.2015.01.014","volume":"29","author":"C Bauch","year":"2015","unstructured":"Bauch C, Bevan S, Woodhouse H, Dilworth C, Walker P (2015) Predicting in vivo phospholipidosis-inducing potential of drugs by a combined high content screening and in silico modelling approach. Toxicol In Vitro 29:621\u2013630","journal-title":"Toxicol In Vitro"},{"key":"1995_CR4","doi-asserted-by":"crossref","first-page":"3844","DOI":"10.1021\/jm0208875","volume":"45","author":"A Cavalli","year":"2002","unstructured":"Cavalli A, Poluzzi E, De Ponti F, Recanatini M (2002) Toward a pharmacophore for drugs inducing the long QT syndrome: insights from a CoMFA study of HERG K+ channel blockers. J Med Chem 45:3844\u20133853","journal-title":"J Med Chem"},{"key":"1995_CR5","doi-asserted-by":"crossref","first-page":"4977","DOI":"10.1021\/jm4004285","volume":"57","author":"A Cherkasov","year":"2014","unstructured":"Cherkasov A, Muratov EN, Fourches D, Varnek A, Baskin II, Cronin M, Dearden J, Gramatica P, Martin YC, Todeschini R, Consonni V, Kuz\u2019min VE, Cramer R, Benigni R, Yang C, Rathman J, Terfloth L, Gasteiger J, Richard A, Tropsha A (2014) QSAR modeling: where have you been? Where are you going to? J Med Chem 57:4977\u20135010","journal-title":"J Med Chem"},{"key":"1995_CR6","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ejmech.2014.12.028","volume":"92","author":"L Goracci","year":"2015","unstructured":"Goracci L, Buratta S, Urbanelli L, Ferrara G, Di Guida R, Emiliani C, Cross S (2015) Evaluating the risk of phospholipidosis using a new multidisciplinary pipeline approach. Eur J Med Chem 92:49\u201363","journal-title":"Eur J Med Chem"},{"key":"1995_CR7","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1109\/TKDE.2008.239","volume":"21","author":"H He","year":"2009","unstructured":"He H, Garcia E (2009) Learning from imbalanced data. IEEE Trans Knowl Data Eng 21:1263\u20131284","journal-title":"IEEE Trans Knowl Data Eng"},{"key":"1995_CR8","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1080\/15376510701857262","volume":"18","author":"NL Kruhlak","year":"2008","unstructured":"Kruhlak NL, Choi SS, Contrera JF, Weaver JL, Willard JM, Hastings KL, Sancilio LF (2008) Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models. Toxicol Mech Methods 18:217\u2013227","journal-title":"Toxicol Mech Methods"},{"key":"1995_CR9","unstructured":"NCATS (2016) \u201cTox21 Data Browser.\u201d \n                        https:\/\/tripod.nih.gov\/tox21\n                        \n                    . Accessed 12 Feb 2017"},{"key":"1995_CR10","unstructured":"PubChem (2013) \u201cTox21 Phase II compound collection\u201d \n                        https:\/\/www.ncbi.nlm.nih.gov\/pcsubstance\/?term=tox21\n                        \n                    . Accessed 12 Feb 2017"},{"key":"1995_CR11","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1177\/153537020122600903","volume":"226","author":"MJ Reasor","year":"2001","unstructured":"Reasor MJ, Kacew S (2001) Drug-induced phospholipidosis: are there functional consequences? Exp Biol Med (Maywood) 226:825\u2013830","journal-title":"Exp Biol Med (Maywood)"},{"key":"1995_CR12","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1177\/1087057113502851","volume":"19","author":"SA Shahane","year":"2014","unstructured":"Shahane SA, Huang R, Gerhold D, Baxa U, Austin CP, Xia M (2014) Detection of phospholipidosis induction: a cell-based assay in high-throughput and high-content format. J Biomol Screen 19:66\u201376","journal-title":"J Biomol Screen"},{"key":"1995_CR13","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/1758-2946-5-47","volume":"5","author":"S Slavov","year":"2013","unstructured":"Slavov S, Pearce B, Buzatu D, Wilkes J, Beger R (2013) Complementary PLS and KNN algorithms for improved 3D-QSDAR consensus modeling of AhR binding. J Cheminform 5:47\u201362","journal-title":"J Cheminform"},{"key":"1995_CR14","doi-asserted-by":"crossref","first-page":"6706","DOI":"10.1016\/j.bmc.2014.08.021","volume":"22","author":"SH Slavov","year":"2014","unstructured":"Slavov SH, Wilkes JG, Buzatu DA, Kruhlak NL, Willard JM, Hanig JP, Beger RD (2014) Computational identification of a phospholipidosistoxicophore using 13C and 15N NMR-distance based fingerprints. Bioorg Med Chem 22:6706\u20136714","journal-title":"Bioorg Med Chem"},{"key":"1995_CR15","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.jmgm.2017.01.012","volume":"72","author":"IB Stoyanova-Slavova","year":"2017","unstructured":"Stoyanova-Slavova IB, Slavov SH, Buzatu DA, Beger RD, Wilkes JG (2017) 3D-SDAR modeling of hERG potassium channel affinity: a case study in model design and toxicophore identification. J Mol Graph Model 72:246\u2013255","journal-title":"J Mol Graph Model"},{"key":"1995_CR16","doi-asserted-by":"crossref","first-page":"4587","DOI":"10.1016\/j.bmcl.2013.06.034","volume":"23","author":"H Sun","year":"2013","unstructured":"Sun H, Xia M, Shahane SA, Jadhav A, Austin CP, Huang R (2013) Are hERG channel blockers also phospholipidosis inducers? Bioorg Med Chem Lett 23:4587\u20134590","journal-title":"Bioorg Med Chem Lett"},{"key":"1995_CR17","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.ab.2009.07.003","volume":"394","author":"SA Titus","year":"2009","unstructured":"Titus SA, Beacham D, Shahane SA, Southall N, Xia M, Huang R, Hooten E, Zhao Y, Shou L, Austin CP, Zheng W (2009) A new homogeneous high-throughput screening assay for profiling compound activity on the human ether-a-go-go-related gene channel. Anal Biochem 394:30\u201338","journal-title":"Anal Biochem"},{"key":"1995_CR18","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.addr.2015.03.003","volume":"86","author":"BO Villoutreix","year":"2015","unstructured":"Villoutreix BO, Taboureau O (2015) Computational investigations of hERG channel blockers: new insights and current predictive models. Adv Drug Deliv Rev 86:72\u201382","journal-title":"Adv Drug Deliv Rev"},{"key":"1995_CR19","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/978-1-4939-6346-1_13","volume-title":"High-throughput screening assays in toxicology","author":"Y Wang","year":"2016","unstructured":"Wang Y, Huang R (2016) Correction of microplate data from high throughput screening. In: Zhu H (ed) High-throughput screening assays in toxicology. Humana Press, Springer Science\u00a0+\u00a0Business Media, New York, pp 123\u2013134"},{"key":"1995_CR20","doi-asserted-by":"crossref","first-page":"57","DOI":"10.2174\/1875397301004010057","volume":"4","author":"Y Wang","year":"2010","unstructured":"Wang Y, Jadhav A, Southal N, Huang R, Nguyen DT (2010) A grid algorithm for high throughput fitting of dose-response curve data. Curr Chem Genomics 4:57\u201366","journal-title":"Curr Chem Genomics"},{"key":"1995_CR21","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1111\/j.1755-5922.2010.00154.x","volume":"29","author":"HJ Witchel","year":"2011","unstructured":"Witchel HJ (2011) Drug-induced hERG block and long QT syndrome. Cardiovasc Ther 29:251\u2013259","journal-title":"Cardiovasc Ther"},{"key":"1995_CR22","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.taap.2011.02.016","volume":"252","author":"M Xia","year":"2011","unstructured":"Xia M, Shahane SA, Huang R, Titus SA, Shum E, Zhao Y, Southall N, Zheng W, Witt KL, Tice RR, Austin CP (2011) Identification of quaternary ammonium compounds as potent inhibitors of hERG potassium channels. Toxicol Appl Pharmacol 252:250\u2013258","journal-title":"Toxicol Appl Pharmacol"}],"container-title":["Archives of Toxicology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00204-017-1995-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00204-017-1995-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00204-017-1995-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,12,5]],"date-time":"2017-12-05T23:00:10Z","timestamp":1512514810000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00204-017-1995-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,27]]},"references-count":22,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["1995"],"URL":"https:\/\/doi.org\/10.1007\/s00204-017-1995-9","relation":{},"ISSN":["0340-5761","1432-0738"],"issn-type":[{"value":"0340-5761","type":"print"},{"value":"1432-0738","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,27]]}}}